We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Multicenter registry of Impella-assisted high-risk percutaneous coronary interventions and cardiogenic shock in Poland (IMPELLA-PL).
- Authors
Pietrasik, Arkadiusz; Gąsecka, Aleksandra; Pawłowski, Tomasz; Sacha, Jerzy; Grygier, Marek; Bielawski, Gabriel; Balak, Wojciech; Sukiennik, Adam; Burzyńska, Paulina; Witkowski, Adam; Warniełło, Mateusz; Rzeszutko, Łukasz; Bartuś, Stanisław; Pawlik, Artur; Kaczyński, Mateusz; Gil, Robert; Kuliczkowski, Wiktor; Reczuch, Krzysztof; Protasiewicz, Marcin; Kleczyński, Pawel
- Abstract
Background: Impella is a percutaneous mechanical circulatory support device for treatment of cardiogenic shock (CS) and high-risk percutaneous coronary interventions (HR-PCIs). IMPELLA-PL is a national retrospective registry of Impella-treated CS and HR-PCI patients in 20 Polish interventional cardiological centers, conducted from January 2014 until December 2021. Aims: We aimed to determine the efficacy and safety of Impella using real-world data from IMPELLA- -PL and compare these with other registries. Methods: IMPELLA-PL data were analyzed to determine primary endpoints: in-hospital mortality and rates of mortality and major adverse cardiovascular and cerebrovascular events (MACCE) at 12 months post-discharge. Results: Of 308 patients, 18% had CS and 82% underwent HR-PCI. In-hospital mortality rates were 76.4% and 8.3% in the CS and HR-PCI groups, respectively. The 12-month mortality rates were 80.0% and 18.2%, and post-discharge MACCE rates were 9.1% and 22.5%, respectively. Any access site bleeding occurred in 30.9% of CS patients and 14.6% of HR-PCI patients, limb ischemia in 12.7% and 2.4%, and hemolysis in 10.9% and 1.6%, respectively. Conclusions: Impella is safe and effective during HR-PCIs, in accordance with previous registry analyses. The risk profile and mortality in CS patients were higher than in other registries, and the potential benefits of Impella in CS require investigation.
- Subjects
POLAND; ARTIFICIAL blood circulation; RESEARCH; ISCHEMIA; PERCUTANEOUS coronary intervention; HEMOLYSIS &; hemolysins; TREATMENT effectiveness; COMPARATIVE studies; HOSPITAL mortality; ST elevation myocardial infarction; CARDIOGENIC shock; DESCRIPTIVE statistics; PATIENT safety; HEMORRHAGE; EVALUATION
- Publication
Polish Heart Journal / Kardiologia Polska, 2023, Vol 81, Issue 11, p1103
- ISSN
0022-9032
- Publication type
Article
- DOI
10.33963/v.kp.97218